A genuine duopoly is rare in any industry, and rarer still in one this large and fast-growing. Yet the obesity-drug market is, for now, a two-horse race: Eli Lilly and Novo Nordisk make the molecules, set much of the pricing, and supply the demand everyone else in the chain depends on. Understanding Eli Lilly and Novo Nordisk is the foundation for understanding the entire GLP-1 economy.
Where this sits in the ripple
Duopoly · Pill · Factory · Delivery · Access · Consumer ripple · Healthcare ripple · Forces (you are here: the centre — the makers)
This is the stone in the water. The makers feed every other ring: the factory that supplies them, the delivery hardware their injections need, and the ripples their success sends through the economy. For the whole map, start at The Boom. These two are also the giants of the broader pharmaceutical link in our Healthcare series. The challengers aiming at them come next, in The Pill.
What this link is
A few terms recur through the series:
- GLP-1 receptor agonist — a drug that imitates a gut hormone to curb appetite and improve blood-sugar control.
- Incretin — the family of gut hormones these drugs are built around; newer drugs target more than one at once.
- Indication — the specific use a drug is approved for. The same molecule can be approved separately for diabetes and for weight management, which widens its market.
The duopoly's strength is that each company owns a molecule with years of patent protection and a head start in manufacturing — a combination rivals cannot copy quickly.
The companies
Eli Lilly (LLY)
What they do: The company that turned obesity into pharma's biggest market. Lilly makes tirzepatide — Mounjaro for diabetes, Zepbound for weight management — alongside a broad drug portfolio. The numbers:. Growth in recent years has been driven overwhelmingly by this franchise. The edge: tirzepatide's strong trial results, a deep pipeline (the oral drug orforglipron and the triple-agonist retatrutide), and an aggressive build-out of manufacturing capacity. The risk: expectations are extremely high, so the share price has a lot of future success priced in. A trial setback, a supply stumble, or pricing pressure would land hard precisely because so much is assumed to go right.
Novo Nordisk (NVO)
What they do: The company that started it all. Novo makes semaglutide — Ozempic for diabetes, Wegovy for weight management — and has decades of focus on metabolic disease. The numbers:. (Danish-listed; figures and the US ADR move with exchange rates.) The edge: first-mover scale, deep expertise, and the distinction of bringing the first oral GLP-1 weight-loss pill to market in early 2026. The risk: Lilly's competing drug has eaten into Novo's lead, and some of Novo's next-generation results have disappointed against very high expectations. A first mover can still lose ground.
A note for non-US readers. Novo Nordisk is not in the S&P 500 — it is a Danish company. It is reachable through a US-listed ADR (NVO), but that adds a currency layer to your returns, and the ordinary shares trade in Copenhagen. We profile it here because no honest map of this market can leave it out.
The bull and bear case
The bull case: a true duopoly with enormous, still under-served demand and real pricing power — an unusually strong competitive position, supported by drugs that keep gaining new approved uses.
The bear case: two-stock concentration cuts both ways. Both companies lean heavily on one drug class; patents will eventually expire; and a crowd of well-funded challengers — covered next — is aiming directly at the prize. High expectations leave little room for disappointment.
Both can be true at once. We are describing the businesses, not telling you what to do about them.
What feeds it, what it feeds
The duopoly is fed by The Factory — the capacity to actually make the drug at scale — and its products reach patients through The Delivery and The Access Layer. The challengers trying to break in are next, in The Pill. To step back to the full map, return to The Boom.
This article is for information only. It is not medical advice and not investment advice or a recommendation to buy or sell any security. TradeRadarNews is not a licensed financial or medical adviser. Figures are accurate as of June 2026 and will change. Markets carry risk, including loss of capital. Rules, taxes, and available products differ by country — do your own research and consult a locally regulated professional.